Effects of HM30181, a P-glycoprotein inhibitor, on the pharmacokinetics and pharmacodynamics of loperamide in healthy volunteers

Sustained Increase in the Oral Bioavailability of Loperamide after a Single Oral Dose of HM30181, a P-glycoprotein Inhibitor, in Healthy Male Participants

(2013) Yu-Jung Cha et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Influence of Concomitant Antiepileptic Drugs on Plasma Lamotrigine Concentration in Adult Japanese Epilepsy Patients

(2012) Yoshiaki Yamamoto et al.   BIOLOGICAL & PHARMACEUTICAL BULLETIN

Tolerability and Pharmacokinetics of a New P-Glycoprotein Inhibitor, HM30181, in Healthy Korean Male Volunteers: Single- and Multiple-Dose Randomized, Placebo-Controlled Studies

(2012) Tae-Eun Kim et al.   CLINICAL THERAPEUTICS

Interaction of HM30181 with P-glycoprotein at the murine blood–brain barrier assessed with positron emission tomography

(2012) Florian Bauer et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

P-glycoprotein Inhibition: The Past, the Present and the Future

(2011) Richard A.J. Darby et al.   CURRENT DRUG METABOLISM

Selective inhibition of MDR1 (ABCB1) by HM30181 increases oral bioavailability and therapeutic efficacy of paclitaxel

(2009) Jin-Oh Kwak et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Tariquidar, a Selective P-glycoprotein Inhibitor, Does Not Potentiate Loperamide’s Opioid Brain Effects in Humans despite Full Inhibition of Lymphocyte P-glycoprotein

(2008) Daniel Kurnik et al.   ANESTHESIOLOGY

The xenobiotic inhibitor profile of cytochrome P4502C8

(2003) Chin-Eng Ong et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY